Stock Code: 000028/200028 Notice No.: 2021-37Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2021
Important content reminder:
1. Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China NationalAccord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no anyfictitious statements, misleading statements, or important omissions carried in this report, and shall take allresponsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.
2. Principal of the Company, Person in Charge of Accounting Works and Person in Charge of Accounting Organ(Accounting Officer) hereby confirm that the Financial Report of the Third Quarterly Report is authentic, accurateand complete.
3. Whether the Third Quarterly Report has been audited or not
□Yes √No
I. Main financial data
(i) Main accounting data and financial indexesWhether it has retroactive adjustment or re-statement on previous accounting data or not
□Yes √No
The Company and whole members of the BOD guarantee that the information disclosed is true,accurate and complete, and there are no any fictitious records, misleading statements orimportant omissions.
| Current period | Increase/decrease in the period compared with the same period of the previous year | Year-begin to period-end | Increase/decrease from year-begin to period-end compared with the same period of the previous year | |
| Operating income (RMB) | 17,046,925,131.18 | 8.51% | 50,210,017,018.57 | 17.09% |
| Net profit attributable to shareholders of the listed company (RMB) | 332,710,261.54 | -6.05% | 1,074,155,274.79 | 7.68% |
| Net profit attributable to shareholders of the | 323,929,049.31 | -8.58% | 1,044,883,457.53 | 6.48% |
| listed company after deducting non-recurring gains and losses (RMB) | ||||
| Net cash flow from operating activities (RMB) | —— | —— | 1,420,066,537.79 | -28.40% |
| Basic earnings per share (RMB/Share) | 0.78 | -6.02% | 2.51 | 7.73% |
| Diluted earnings per share (RMB/Share) | 0.78 | -6.02% | 2.51 | 7.73% |
| Weighted average ROE | 2.29% | 0.36 percentage point down | 7.51% | 0.05 percentage point down |
| At the end of the reporting period | At the end of last year | Increase/decrease at the period-end compared with the end of the previous year | ||
| Total assets (RMB) | 44,855,599,672.17 | 39,594,533,471.65 | 13.29% | |
| Net assets attributable to shareholder of listed company (RMB) | 14,679,445,950.04 | 13,948,322,652.33 | 5.24% | |
(ii) Items and amounts of non-recurring profit (gains)/losses
√ Applicable □ Not applicable
In RMB
| Item | Amount for the period | Amount from year-begin to period-end | Note |
| Gains/losses from the disposal of non-current asset (including the write-off that accrued for impairment of assets) | 1,412,736.93 | 610,707.82 | Mainly the gains of disposal of the right-of-use assets from store lease surrender. |
| Governmental subsidy reckoned into current gains/losses (not including the subsidy enjoyed in quota or ration according to national standards, which are closely relevant to enterprise’s business) | 14,898,997.98 | 50,262,339.66 | Mainly the various special subsidies and tax rebates received in the Period. |
| When an enterprise acquires a subsidiary, associated enterprise and joint venture, the investment cost is less than the income generated by the fair value of the identifiable net assets of the invested entity | 578,610.41 | ||
| Switch back of provision for depreciation of account receivable and contract assets that are individually tested for impairment | 10,000.00 | 98,994.76 |
| Other non-operating income and expenditure except for the aforementioned items | -3,156,204.15 | 4,384,579.81 | Mainly the non-operating income arising from write off funds that do not need to be paid, and non-operating expenses arising from public welfare donation expenses, payment of fines and late fees. |
| Other gains/losses satisfy a definition of extraordinary gains/losses | 673,726.22 | 2,391,162.12 | |
| Less: impact on income tax | 453,104.34 | 13,415,430.35 | |
| Impact on minority shareholders’ equity (post-tax) | 4,604,940.41 | 15,639,146.97 | |
| Total | 8,781,212.23 | 29,271,817.26 | -- |
Other gain/loss items that qualified the definition of non-recurring profit (gains)/losses:
□ Applicable √ Not applicable
The Company does not have other gain/loss items that qualified the definition of non-recurring profit (gains)/lossesExplanation on those non-recurring gain/loss listed in the “Q&A Announcement No.1 on Information Disclosure for Companies OfferingTheir Securities to the Public --- Extraordinary Profit/loss” defined as recurring gain/loss
□ Applicable √ Not applicable
The Company does not have the non-recurring gain/loss listed in the “Q&A Announcement No.1 on Information Disclosure forCompanies Offering Their Securities to the Public --- Extraordinary Profit/loss” defined as recurring gain/loss(iii) Particulars about changes in items of main accounting data and financial index and explanations ofreasons
√ Applicable □Not applicable
(1) Accounts receivable: has an increase of 4,572.2236 million yuan from the beginning of the period with a growth rate of 33.13%,mainly because the account receivable increase with the expansion of sales in the period, as well as the delay appropriation from medicalinsurance and increase in turnover days of account receivable;
(2) Receivable financing: has a decrease of 657.8605 million yuan from the beginning of the period with a growth rate of -46.82%,mainly because the discounted bank acceptance increased in the period;
(3) Contract assets: has an increase of 6.1211 million yuan from the beginning of the period with a growth rate of 40.33%, mainlybecause as the sales of equipment increase, the receivable quality margin for equipment business increases accordingly;
(4) Construction in progress: has an increase of 30.8528 million yuan from the beginning of the period with a growth rate of 66.16%,mainly due to the increase of investment for ERP system construction;
(5)Short-term borrowings: has an increase of 1,668.7105 million yuan from the beginning of the period with a growth rate of 103.51%,mainly due to the increase in invoice financing of account payable;
(6) Accounts payable: has an increase of 3,049.7387 million yuan from the beginning of the period with a growth rate of 39.62%, mainlybecause as the growth of business, the purchasing volume and account payable increased accordingly;
(7) Receipts in advance: has an increase of 4.8947 million yuan from the beginning of the period with a growth rate of 39.63%, mainlybecause the lease payments received in advance increased;
(8) Interest payable: has a decrease of 22.1891 million yuan from the beginning of the period with a growth rate of -62.38%, mainlybecause as the decrease of non-recourse factoring financing for account receivable, interest payable decreases accordingly;
(9) Dividend payable: has an increase of 24.1576 million yuan from the beginning of the period with a growth rate of 378.09%, mainlybecause the accrual of dividend payable to minority shareholders increased;
(10)Long-term borrowings: as an increase of 29.9966 million yuan from the beginning of the period with a growth rate of 94.81%,mainly due to obtaining the long-term credit loans of dedicated equity acquisition;
(11) Finance costs: has a year-on-year increase of 78.9280million yuan with a growth rate of 91.05%, mainly because in 2020, theCompany has a large-scale acquisitions, and the corresponding consideration for equity acquisition are paid successively, the interestincome from deposit declined on a year-on-year basis;
(12) Other incomes: has a year-on-year increase of 23.2876 million yuan with a growth rate of 50.42%, mainly because various specialsubsidies and tax relief received in the period increased on a year-on-year basis;
(13) Impairment losses: has a year-on-year decrease of 6.6624 million yuan with a growth rate of -119.34%, mainly due to the reversal ofinventory falling price reserves in the period;
(14) Gains on disposal of assets: has a year-on-year decrease of 6.3585 million yuan with a growth rate of -86.83%, mainly because thegains on disposal of right-to-use assets arising from off-lease retail stores declined on a year-on-year basis;
(15) Non-operating income: has a year-on-year increase of 6.4051 million yuan with a growth rate of 65.50%, mainly because theaccount payable that do not need to be paid are written off in the period;
(16) Non-operating expenses: has a year-on-year decrease of 10.8463 million yuan with a growth rate of -53.18%, mainly because alarge amount of litigation compensation occurred in the same period of the previous year;
(17) Other cash receipts relating to operating activities: has a year-on-year decrease of 664.6786 million yuan with a growth rate of-54.65%, mainly because the special reserve funds received in the period declined on a year-on-year basis;
(18) Cash payments to and on behalf of employees: has a year-on-year increase of 576.5452 million yuan with a growth rate of 30.13%,mainly because the new enterprise consolidated in second half of 2020 made the cash paid to and for the employees increased in theperiod, and as the expansion of the Company, new pharmacies and number of employees increased, the labor costs are rising rigidly;
(19) Cash receipts from returns of investments: has a year-on-year decrease of 16.0302 million yuan with a growth rate of -84.25%,mainly because the investment project withdrawal payment received from Sinopharm Zhongjin Medical Industry Fund declined on ayear-on-year basis;
(20) Cash received from returns on investments: has a year-on-year decrease of 135.7757 million yuan with a growth rate of -85.09%,mainly because the dividends received from investment in associated enterprise declined on a year-on-year basis;
(21) Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets: has a year-on-year decrease of
4.5941million yuan with a growth rate of -87.10%, mainly because the cash received from disposal of fixed assets decreased on ayear-on-year basis;
(22) Other cash receipts relating to investing activities: has a year-on-year decrease of 21.9850 million yuan with a growth rate of-99.75%, mainly because in the same period of previous year, subsidiary of the Company - Sinopharm Holding Guoda Drugstore Co.,Ltd. (hereinafter referred to as Guoda Drugstore) consolidated the subsidiary - Pudong New Area of Shanghai Pharmaceutical MedicineLtd under the same control, the balance of cash pool originally collected to its former parent company Sinopharm Group Co., Ltd arereceived, and there is no such event occurred in the period;
(23) Total cash inflows from investing activities: has a year-on-year decrease of 178.3851 million yuan with a growth rate of -86.63%,mainly because the dividends received from investment in associated enterprise declined on a year-on-year basis;
(24) Cash payments for investments: has a year-on-year increase of 87.8213 million yuan with a growth rate of 309.12%, mainly becausethe fees for store exchange paid by subsidiary Guoda Drugstore in the period increased on a year-on-year basis;
(25) Net cash payments for acquisition of subsidiaries and other business units: has a year-on-year decrease of 2,283.6644 million yuanwith a growth rate of -95.77%, mainly because compared with same period of last year, the account of subsidiary acquisition paid by thesubsidiary Guoda Drugstore in the period declined;
(26) Cash payments related to other investing activities: has a year-on-year decrease of 5.00 million yuan with a growth rate of -100.00%,mainly due to the payment of long-term deposits in the same period of last year, and there was no such event occurred in the period;
(27) Total cash outflows from investing activities: has a year-on-year decrease of 2,147.3163 million yuan with a growth rate of -82.37%,mainly because compared with same period of last year, the account of subsidiary acquisition paid by the subsidiary Guoda Drugstore inthe period declined;
(28) Net cash flows from investing activities: has a year-on-year increase of 1,968.9313 million yuan with a growth rate of 82.00%,
mainly because compared with same period of last year, the account of subsidiary acquisition paid by the subsidiary Guoda Drugstore inthe period declined;
(29) Cash proceeds from investments by others: has a year-on-year increase of 17.2061 million yuan with a growth rate of 100.00%,mainly because received the investment from minorities in the period, and there was no such event occurred in the same period of theprevious year;
(30) Other cash receipts relating to financing activities: has a year-on-year decrease of 215.6720 million yuan with a growth rate of-67.47%, mainly due to the decrease in borrowing received from minority shareholders in the period, and the mature money orderdeposit collected in the period decline on a year-on-year basis;
(31) Cash repayments for debts: has a year-on-year increase of 673.5614 million yuan with a growth rate of 214.85%, mainly due to theincrease in repayment of loans in the period;
(32)Effect of foreign exchange rate changes on cash and cash equivalents: has a year-on-year increase of 0.4410 million yuan with agrowth rate of 879.85%, mainly due to the impact of exchange rate movements;
(33) Net increase of cash and cash equivalents: has a year-on-year increase of 1,082.7871 million yuan with a growth rate of 59.59%,mainly because compared with same period of last year, the account of subsidiary acquisition paid by the subsidiary Guoda Drugstore inthe period declined;
(34) Cash and cash equivalents at beginning of the year: has a year-on-year decrease of 3,020.9579 million yuan with a growth rate of-35.85%, mainly because in 2020, the Company have large-scale acquisitions, and corresponding consideration of equity acquisition arepaid successively, resulting in a decline in balance of cash and cash equivalents at the beginning of the year.II. Shareholders Information(i) Total number of common shareholders and preference shareholders with voting rights recovered and topten common shareholders
In Share
| Total common shareholders at the end of report period | 45,126 | Total preference shareholders with voting rights recovered at end of reporting period (if applicable) | 0 | |||||
| Top ten shareholders | ||||||||
| Shareholder’s name | Nature of shareholder | Proportion of shares held | Amount of shares held | Amount of restricted shares held | Information of shares pledged, tagged or frozen | |||
| State of share | Amount | |||||||
| Sinopharm Group Co., Ltd. | State-owned legal person | 56.06% | 239,999,991 | 5,505,770 | ||||
| FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND | Foreign corporation | 2.52% | 10,802,495 | |||||
| Hong Kong Securities Clearing Company Ltd | Foreign corporation | 1.96% | 8,384,966 | |||||
| China National Pharmaceutical | State-owned legal person | 1.24% | 5,323,043 | |||||
| Foreign Trade Corp. | ||||||
| National Social Security Fund- portfolio 413 | Domestic non state-owned corporation | 1.06% | 4,530,032 | |||
| BBH BOS S/A FIDELITY FD - CHINA FOCUS FD | Foreign corporation | 0.78% | 3,358,761 | |||
| CPIC Fund- China Pacific Life Insurance Co., Lt. - participating insurance -CPIC fund PICC Stock Relative Income (guaranteed bonus)single asset management plan | Domestic non state-owned corporation | 0.70% | 2,976,701 | |||
| Fidelity Investment Management (Hong Kong) Limited - Client’s fund | Foreign corporation | 0.54% | 2,308,237 | |||
| VANGUARD EMERGING MARKETS STOCK INDEX FUND | Foreign corporation | 0.40% | 1,697,229 | |||
| ICBC- CPIC Desheng Small Selected Securities Investment Funds | Domestic non state-owned corporation | 0.38% | 1,632,000 | |||
| Top ten shareholders with unrestricted shares held | ||||||
| Shareholder’s name | Amount of unrestricted shares held | Type of shares | ||||
| Type | Amount | |||||
| Sinopharm Group Co., Ltd. | 234,494,221 | RMB ordinary shares | 234,494,221 | |||
| FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND | 10,802,495 | Domestic listed foreign shares | 10,802,495 | |||
| Hong Kong Securities Clearing Company Ltd | 8,384,966 | RMB ordinary shares | 8,384,966 | |||
| China National Pharmaceutical Foreign Trade Corp. | 5,323,043 | RMB ordinary shares | 5,323,043 | |||
| National Social Security Fund- portfolio 413 | 4,530,032 | RMB ordinary shares | 4,530,032 | |||
| BBH BOS S/A FIDELITY FD - CHINA FOCUS FD | 3,358,761 | Domestic listed foreign shares | 3,358,761 | |||
| CPIC Fund- China Pacific Life Insurance Co., Lt. - participating | 2,976,701 | RMB ordinary shares | 2,976,701 | |||
| insurance -CPIC fund PICC Stock Relative Income (guaranteed bonus)single asset management plan | |||
| Fidelity Investment Management (Hong Kong) Limited - Client’s fund | 2,308,237 | RMB ordinary shares | 2,308,237 |
| VANGUARD EMERGING MARKETS STOCK INDEX FUND | 1,697,229 | Domestic listed foreign shares | 1,697,229 |
| ICBC- CPIC Desheng Small Selected Securities Investment Funds | 1,632,000 | RMB ordinary shares | 1,632,000 |
| Explanation on associated relationship among the aforesaid shareholders | Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have the same actual controller, which is China National Pharmaceutical Group Corporation. It is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information Disclosure on Change of Shareholding for Listed Companies. | ||
(ii) Total shareholders with preferred stock held and shares held by top ten shareholders with preferred stockheld
□ Applicable √ Not applicable
III. Other significant events
□ Applicable √ Not applicable
IV. Quarterly financial statements(i) Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
| Item | September 30, 2021 | December 31, 2020 |
| Current assets: | ||
| Cash and bank balances | 5,030,550,238.21 | 5,998,204,295.87 |
| Settlement provisions | ||
| Capital lent | ||
| Trading financial assets | ||
| Derivative financial assets | ||
| Notes receivable | 486,665,614.67 | 622,115,477.04 |
| Accounts receivable | 18,372,194,576.17 | 13,799,971,014.22 |
| Receivable financing | 747,127,225.28 | 1,404,987,700.38 |
| Advances to suppliers | 577,047,357.55 | 480,313,574.71 |
| Insurance receivable | ||
| Reinsurance receivables | ||
| Contract reserve of reinsurance receivable |
| Other receivables | 588,663,715.06 | 535,228,747.69 |
| Including: Interest receivable | ||
| Dividend receivable | ||
| Buying back the sale of financial assets | ||
| Inventories | 7,731,292,407.49 | 6,285,010,674.46 |
| Contract assets | 21,298,841.34 | 15,177,731.64 |
| Assets held for sale | ||
| Non-current asset due within one year | ||
| Other current assets | 117,800,222.89 | 121,082,863.45 |
| Total current assets | 33,672,640,198.66 | 29,262,092,079.46 |
| Non-current assets: | ||
| Loans and payments on behalf | ||
| Debt investment | ||
| Other debt investment | ||
| Long-term account receivable | ||
| Long-term equity investments | 2,506,592,540.54 | 2,287,019,627.99 |
| Other equity instruments investment | 99,488,340.28 | 99,488,340.28 |
| Other non-current financial assets | 135,974,908.51 | 120,972,350.24 |
| Investment properties | 115,666,257.13 | 127,444,379.94 |
| Fixed assets | 846,208,850.06 | 854,191,083.27 |
| Construction in progress | 77,483,997.80 | 46,631,190.23 |
| Productive biological asset | ||
| Oil and gas asset | ||
| Right-of-use assets | 2,602,364,849.90 | 2,356,952,392.99 |
| Intangible assets | 738,312,505.33 | 734,345,179.40 |
| Expense on Research and Development | ||
| Goodwill | 2,932,001,316.63 | 2,747,375,281.11 |
| Long-term prepaid expenses | 547,554,650.71 | 457,705,276.09 |
| Deferred tax assets | 109,492,207.51 | 92,118,767.81 |
| Other non-current assets | 471,819,049.11 | 408,197,522.84 |
| Total non-current assets t | 11,182,959,473.51 | 10,332,441,392.19 |
| Total assets | 44,855,599,672.17 | 39,594,533,471.65 |
| Current liabilities: | ||
| Short-term borrowings | 3,280,897,558.10 | 1,612,187,020.12 |
| Loan from central bank | ||
| Capital borrowed | ||
| Trading financial liability | ||
| Derivative financial liability | ||
| Notes payable | 7,348,840,877.78 | 7,520,165,274.69 |
| Accounts payable | 10,747,189,833.18 | 7,697,451,142.50 |
| Receipts in advance | 17,247,134.79 | 12,352,466.64 |
| Contract liabilities | 326,085,220.43 | 368,600,357.14 |
| Selling financial asset of |
| repurchase | ||
| Absorbing deposit and interbank deposit | ||
| Security trading of agency | ||
| Security sales of agency | ||
| Employee benefits payable | 277,589,432.45 | 357,212,047.10 |
| Tax payable | 278,421,837.51 | 316,867,149.16 |
| Other payables | 1,499,776,310.73 | 1,599,166,881.14 |
| Including: Interest payable | 13,383,522.61 | 35,572,620.82 |
| Dividend payable | 30,546,882.17 | 6,389,320.96 |
| Commission charge and commission payable | ||
| Reinsurance payable | ||
| Liability held for sale | ||
| Non-current liabilities due within one year | 815,092,369.38 | 748,732,059.89 |
| Other current liabilities | 20,574,820.83 | 24,787,078.55 |
| Total current liabilities | 24,611,715,395.18 | 20,257,521,476.93 |
| Non-current liabilities: | ||
| Insurance contract reserve | ||
| Long-term borrowings | 61,633,794.44 | 31,637,173.89 |
| Bonds payable | ||
| Including: Preferred stock | ||
| Perpetual capital securities | ||
| Lease liabilities | 1,414,900,980.86 | 1,303,054,163.90 |
| Long-term payables | 6,938,189.00 | 6,938,189.00 |
| Long-term employee benefits payable | 1,262,000.00 | 1,319,000.00 |
| Provisions | 68,663,166.79 | 68,808,166.79 |
| Deferred income | 88,319,436.13 | 89,843,583.37 |
| Deferred tax liabilities | 192,406,210.58 | 205,921,408.66 |
| Other non-current liabilities | 611,494,372.76 | 740,862,989.59 |
| Total non-current liabilities | 2,445,618,150.56 | 2,448,384,675.20 |
| Total liabilities | 27,057,333,545.74 | 22,705,906,152.13 |
| Equity | ||
| Share capital | 428,126,983.00 | 428,126,983.00 |
| Other equity instrument | ||
| Including: Preferred stock | ||
| Perpetual capital securities | ||
| Capital surplus | 4,371,864,522.76 | 4,372,504,053.72 |
| Less: Inventory shares | ||
| Other comprehensive income | 38,592,158.00 | 38,483,017.72 |
| Reasonable reserve | ||
| Surplus reserve | 214,063,491.50 | 214,063,491.50 |
| Provision of general risk | ||
| Retained earnings | 9,626,798,794.78 | 8,895,145,106.39 |
| Total equity attributable to owners of the parent | 14,679,445,950.04 | 13,948,322,652.33 |
| Non-controlling interests | 3,118,820,176.39 | 2,940,304,667.19 |
| Total equity | 17,798,266,126.43 | 16,888,627,319.52 |
| Total liabilities and equity | 44,855,599,672.17 | 39,594,533,471.65 |
Legal Representative: Lin ZhaoxiongFinancial controller: Gu GuolinHead of Accounting Department: Wang Ying
2. Consolidated Profit Statement (from the year-begin to the period-end)
In RMB
| Item | Current period | Last period |
| I. Total operating income | 50,210,017,018.57 | 42,880,505,125.63 |
| Including: Operating revenue | 50,210,017,018.57 | 42,880,505,125.63 |
| Interest income | ||
| Insurance gained | ||
| Commission charge and commission income | ||
| II. Total operating cost | 48,889,105,650.99 | 41,581,721,662.96 |
| Including: Operating costs | 44,355,137,220.69 | 37,944,504,626.84 |
| Interest expense | ||
| Commission charge and commission expense | ||
| Cash surrender value | ||
| Net amount of expense of compensation | ||
| Net amount of withdrawal of insurance contract reserve | ||
| Bonus expense of guarantee slip | ||
| Reinsurance expense | ||
| Tax and surcharges | 118,668,192.68 | 110,209,795.96 |
| Selling expenses | 3,489,636,134.44 | 2,749,994,678.55 |
| Administrative expenses | 760,050,554.53 | 690,327,040.05 |
| R&D expense | ||
| Finance costs | 165,613,548.65 | 86,685,521.56 |
| Including: Interest expenses | 221,745,036.68 | 202,695,852.03 |
| Interest income | 58,695,611.60 | 112,936,201.56 |
| Add: other incomes | 69,475,290.52 | 46,187,696.54 |
| Investment income (Loss is listed with “-”) | 232,226,696.90 | 211,950,494.51 |
| Including: Investment income from associates | 237,971,923.43 | 247,559,119.49 |
| Income from the | -11,674,941.64 | -40,767,172.72 |
| derecognition of financial assets measured at amortised cost (Loss is listed with “-”) | ||
| Exchange income (Loss is listed with “-”) | ||
| Net exposure hedging income (Loss is listed with “-”) | ||
| Income from change of fair value (Loss is listed with “-”) | ||
| Credit impairment losses/ (Loss is listed with “-”) | -31,552,326.70 | -29,083,726.06 |
| Impairment losses (Loss is listed with “-”) | 1,079,690.03 | -5,582,665.20 |
| Gain on disposal of assets (Loss is listed with “-”) | 964,385.82 | 7,322,907.21 |
| III. Operating profits (Loss is listed with “-”) | 1,593,105,104.15 | 1,529,578,169.67 |
| Add: Non-operating income | 16,183,608.97 | 9,778,532.18 |
| Less: Non-operatingexpenses | 9,550,290.33 | 20,396,541.07 |
| IV. Total profit (Loss is listed with “-”) | 1,599,738,422.79 | 1,518,960,160.78 |
| Less: Income tax expenses | 328,358,528.63 | 297,799,939.72 |
| V. Net profit (Net loss is listed with “-”) | 1,271,379,894.16 | 1,221,160,221.06 |
| (i) Classify by business continuity | ||
| 1. Profit or loss from continuing operations (net loss listed with ‘-”) | 1,271,379,894.16 | 1,221,160,221.06 |
| 2.termination of net profit (net loss listed with ‘-”) | ||
| (ii) Classify by ownership | ||
| 1. Owners of the parent | 1,074,155,274.79 | 997,585,746.42 |
| 2. Non-controlling interests | 197,224,619.37 | 223,574,474.64 |
| VI. Other comprehensive income, net of tax | 109,140.28 | 143,939.42 |
| Other comprehensive income, net of tax, attributable to owners of the parent | 109,140.28 | 143,939.42 |
| (i) Other comprehensive income items which will not be reclassified subsequently to profit of loss | ||
| 1.Changes of the defined benefit plans that re-measured | ||
| 2.Other comprehensive income under equity method that cannot be transfer to gain/loss | ||
| 3.Change of fair value of investment in other equity instrument | ||
| 4.Fair value change of enterprise's credit risk | ||
| 5. Other | ||
| (ii) Other comprehensive income that will be reclassified to profit or loss | 109,140.28 | 143,939.42 |
| 1. Other comprehensive income using the equity method that may be reclassified to profit or loss | 109,140.28 | 143,939.42 |
| 2.Change of fair value of |
Enterprise combine under the same control in the Period, the combined party realized net profit of 0.00 Yuan before combination, andrealized 0.00 Yuan at last period for combined partyLegal Representative: Lin ZhaoxiongFinancial controller: Gu GuolinHead of Accounting Department: Wang Ying
3. Consolidated Cash Flow Statement (from the year-begin to the period-end)
In RMB
| Item | Current period | Last period |
| I. Cash flows from operating activities: | ||
| Cash received from sales of good or rendering of services | 50,434,425,085.34 | 42,418,077,097.10 |
| Net increase of customer deposit and interbank deposit | ||
| Net increase of loan from central bank | ||
| Net increase of capital borrowed from other financial institution | ||
| Cash received from original insurance contract fee | ||
| Net cash received from reinsurance business | ||
| Net increase of insured savings and investment | ||
| Cash received from interest, commission charge and commission | ||
| Net increase of capital borrowed |
| other debt investment | ||
| 3.Amount of financial assets re-classify to other comprehensive income | ||
| 4.Credit impairment provision for other debt investment | ||
| 5.Cash flow hedging reserve | ||
| 6.Translation differences arising on translation of foreign currency financial statements | ||
| 7.Other | ||
| Net after-tax of other comprehensive income attributable to minority shareholders | ||
| VII. Total comprehensive income | 1,271,489,034.44 | 1,221,304,160.48 |
| Total comprehensive income attributable to owners of the parent | 1,074,264,415.07 | 997,729,685.84 |
| Total comprehensive income attributable to non-controlling interests | 197,224,619.37 | 223,574,474.64 |
| VIII. Earnings per share: | ||
| (i) Basic earnings per share | 2.51 | 2.33 |
| (ii) Diluted earnings per share | 2.51 | 2.33 |
| Net increase of returned business capital | ||
| Net cash received by agents in sale and purchase of securities | ||
| Receipts of taxes and surcharges refunds | 9,785,028.42 | 10,784,614.07 |
| Other cash receipts relating to operating activities | 551,569,390.53 | 1,216,248,037.55 |
| Total cash inflows from operating activities | 50,995,779,504.29 | 43,645,109,748.72 |
| Cash payments for goods and services | 44,590,896,502.94 | 37,533,521,802.87 |
| Net increase of customer loans and advances | ||
| Net increase of deposits in central bank and interbank | ||
| Cash paid for original insurance contract compensation | ||
| Net increase of capital lent | ||
| Cash paid for interest, commission charge and commission | ||
| Cash paid for bonus of guarantee slip | ||
| Cash payments to and on behalf of employees | 2,490,251,009.84 | 1,913,705,773.98 |
| Payments of all types of taxes and surcharges | 1,163,054,174.01 | 1,148,433,266.37 |
| Other cash payments relating to operating activities | 1,331,511,279.71 | 1,066,101,719.26 |
| Total cash outflows from operating activities | 49,575,712,966.50 | 41,661,762,562.48 |
| Net cash flows from operating activities | 1,420,066,537.79 | 1,983,347,186.24 |
| II. Cash flows from investing activities: | ||
| Cash receipts from returns of investments | 2,997,441.73 | 19,027,649.76 |
| Cash received from returns on investments | 23,798,335.31 | 159,574,046.42 |
| Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets | 680,564.38 | 5,274,705.47 |
| Net cash received from disposal of subsidiaries and other units | ||
| Other cash receipts relating to investing activities | 54,984.60 | 22,040,000.00 |
| Total cash inflows from investing activities | 27,531,326.02 | 205,916,401.65 |
| Cash payments to acquire fixed assets, intangible assets and other long-term assets | 242,406,946.82 | 188,880,164.05 |
| Cash payments for investments | 116,231,775.64 | 28,410,468.41 |
| Net increase of mortgaged loans | ||
| Net cash payments for acquisition of subsidiaries and other business units | 100,950,637.41 | 2,384,615,064.76 |
| Cash payments related to other | 5,000,000.00 |
| investing activities | ||
| Total cash outflows from investing activities | 459,589,359.87 | 2,606,905,697.22 |
| Net cash flows from investing activities | -432,058,033.85 | -2,400,989,295.57 |
| III. Cash flows from financing activities | ||
| Cash proceeds from investments by others | 17,206,123.00 | |
| Incl: Cash receipts from capital contributions from non-controlling interests of subsidiaries | 17,206,123.00 | |
| Cash receipts from borrowings | 922,684,894.52 | 801,520,037.57 |
| Other cash receipts relating to financing activities | 103,972,601.77 | 319,644,627.50 |
| Total cash inflows from financing activities | 1,043,863,619.29 | 1,121,164,665.07 |
| Cash repayments for debts | 987,061,372.10 | 313,500,000.00 |
| Cash payments for distribution of dividends or profit and interest expenses | 601,040,337.18 | 545,931,923.60 |
| Incl: Dividends or profit paid to non-controlling shareholders of subsidiaries | 54,850,818.34 | 62,338,791.80 |
| Other cash payments relating to financing activities | 1,178,389,883.78 | 1,661,056,163.63 |
| Total cash outflows from financing activities | 2,766,491,593.06 | 2,520,488,087.23 |
| Net cash flows from financing activities | -1,722,627,973.77 | -1,399,323,422.16 |
| IV. Effect of foreign exchange rate changes on cash and cash equivalents | 390,912.15 | -50,126.70 |
| V. Net increase of cash and cash equivalents | -734,228,557.68 | -1,817,015,658.19 |
| Add: Cash and cash equivalents at beginning of the year | 5,405,113,257.99 | 8,426,071,170.16 |
| VI. Cash and cash equivalents at end of year | 4,670,884,700.31 | 6,609,055,511.97 |
(ii) Explanation on financial statement adjustment
1. Financial statement adjustment at the beginning of the first year when implementation of new leasingstandards from 2021
□ Applicable √ Not applicable
2. Retrospective adjustment of the comparative data for initial implementation of new leasing standards from2021
□ Applicable √ Not applicable
(iii) Audit report
Whether the 3
rd
quarterly report has been audited or not
□Yes √ No
The 3rd
quarterly report of the Company has not been audited.
Board of Directors of
China National Accord Medicines Corporation Ltd.
20 October 2021